Akebia Therapeutics, Inc. (NASDAQ:AKBA)
| Market Cap | 224.83M-70.4% |
| Revenue (ttm) | 219.06M+7.5% |
| Net Income | -29.67M+18.7% |
| EPS | -0.11+36.1% |
| Shares Out | 268.26M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,267,552.369 |
| Open | 0.85 |
| Previous Close | 0.87 |
| Day's Range | 0.84 - 0.86 |
| 52-Week Range | 0.81 - 3.20 |
| Beta | 0.23 |
| Analysts | Buy |
| Price Target | 1.00(+19.32%) |
| Earnings Date | Nov 9, 2026 |
Insiders here have filed 1 Form 4 in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About AKBA
Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney disease (CKD) in adult patients, encompassing both those dependent on dialysis and those who are not. Akebia also markets Auryxia, a ferric citrate product used to manage serum phosphorus levels in adult CKD patients undergoing dialysis, and to treat iron deficiency anemia in adult CKD patients who are not on dialysis. The company has several key collaboration agreements: with Otsuka Pharmaceutical Co. Ltd. for vadadustat's development and commercialization across major regions including the United States, European Union, Russia, China, Australia, Canada, and the Middle East; with Mitsubishi Tanabe Pharma Corporation for vadadustat in Japan and other Asian territories; and a research and licensing deal with Janssen Pharmaceutica NV pertaining to hypoxia-inducible factor prolyl hydroxylase targeted compounds globally.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$AKBA stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in AKBA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by AKBA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
AKBA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
AKBA Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Ending balance | $77.78M | 39.87% |
| Beginning balance | $77.09M | 39.52% |
| Current provisions related to sales in current year | $40.22M | 20.62% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New AKBA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to AKBA from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in AKBA
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $7.27M |
| IWMiShares Russell 2000 ETF | $6.05M |
| VXFVanguard Extended Market ETF | $2.84M |
| IWOiShares Russell 2000 Growth ETF | $1.78M |
| FESMFidelity Enhanced Small Cap ETF | $1.72M |
| VTWOVanguard Russell 2000 ETF | $1.36M |
Estimated from each fund’s disclosed top holdings × AUM
AKBA Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from AKBA’s recent data — informational, not investment advice